skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration

Anticipate the outcomes and implications of 2013’s key FDA approval decisions.

 

Although 2012 witnessed the FDA approve 39 new drugs and biological entities, drugs approved for the treatment of disorders of the central nervous system (CNS) accounted for just two of these successful candidates – Aubagio (teriflunomide) gained approval for multiple sclerosis (MS) and Fycompa (perampanel) for epilepsy.

 

In 2013 however, we anticipate a far more productive outlook for the CNS sector. Several promising candidates for psychiatric and neurological indications were filed for approval in the US in 2012, with at least six expected to demonstrate significant clinical benefit to win FDA approval over the next 12 months.

 

 

Download your free whitepaper summary

Understand our expert view on the likely impact and implications with this free White Paper summary.

 



 

CNS_Catalyst

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888 670 8900
  • US Toll           : +1 908 547 2200
  • UK & Europe : +44 (20) 337 73737
  • Australia        : +61 2 8705 6907
  • Japan              : +81 3 6273 4260

Or please submit your inquiry via the form so that we can provide you the best possible customer service.

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: